Trial Profile
A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Nov 2023 This trial has been completed in Slovakia and Hungary, according to European Clinical Trials Database record.
- 12 Nov 2023 This trial has been completed in Slovakia and Hungary, according to European Clinical Trials Database record.
- 17 May 2023 Planned End Date changed from 8 Nov 2025 to 26 Mar 2025.